Glaukos share price today

(GKOS)

Glaukos share price is $150.88 & ₹12,821.18 as on 21 Dec 2024, 2.30 'hrs' IST

$150.88

▲

7.14

(4.97%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Glaukos share price in Dollar and Rupees. Guide to invest in Glaukos from India. Also see the sentimental analysis on Indian investors investing in Glaukos. Get details on the Indian mutual funds that are investing in Glaukos. Get Analyst recommendations and forecasts along with all the Glaukos's financials.

Glaukos share price movements

Today's Low: $142.84
Today's High: $150.99
$150.88
5.33%
Downside
Day's Volatility :5.4%
Upside
0.07%
52 Weeks Low: $74.75
52 Weeks High: $151.12
$150.88
50.46%
Downside
52 Weeks Volatility :50.54%
Upside
0.16%

Glaukos Returns

Period	Glaukos Corp	Sector (Health Care)	Index (Russel 2000)
3 Months	17.89%	-11.1%	0.0%
6 Months	34.74%	-6.0%	0.0%
1 Year	83.24%	2.7%	0.0%
3 Years	230.51%	0.6%	-19.7%

Glaukos Key Statistics

in dollars & INR

Previous Close	$143.74
Open	$141.53
Today's High	$150.99
Today's Low	$142.84
Market Capitalization	$7.9B
Today's Volume	$979.7K
52 Week High	$151.12
52 Week Low	$74.745
Revenue TTM	$360.3M
EBITDA	$-80.7M
Earnings Per Share (EPS)	$-2.93
Profit Margin	-41.51%
Quarterly Earnings Growth YOY	18.96%
Return On Equity TTM	-26.1%

How to invest in Glaukos from India?

It is very easy for Indian residents to invest directly in Glaukos from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Glaukos stock in both Indian Rupees (INR) and US Dollars (USD). Search for Glaukos or GKOS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Glaukos or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Glaukos shares which would translate to 0.006 fractional shares of Glaukos as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Glaukos, in just a few clicks!

Returns in Glaukos for Indian investors in Rupees

Investment Value

₹1,00,000

Glaukos investment value today

Current value as on today

₹1,85,436

Returns

₹85,436

(+85.44%)

Returns from Glaukos Stock

₹83,240 (+83.24%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Glaukos

Period: Sep 21, 2024 to Dec 20, 2024. Change in 30 Days versus previous period

Search volume for Glaukos on INDmoney from India has grown in the last 30 days as on Dec 21, 2024. 0% more investors are searching Glaukos in the last 30 days versus the previous period.

Global Institutional Holdings in Glaukos

BlackRock Inc
14.58%
FMR Inc
11.94%
Vanguard Group Inc
10.65%
Wellington Management Company LLP
3.96%
State Street Corp
3.54%
Ameriprise Financial Inc
2.97%

Analyst Recommendation on Glaukos

Buy

75%Buy

25%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Glaukos(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Glaukos

What analysts predicted

Downside of 2.41%

Current:

$150.88

Target:

$147.25

Insights on Glaukos

Price Movement
In the last 7 days, GKOS stock has moved up by 8.6%
Increasing Revenue
Revenue is up for the last 5 quarters, 78.04M → 96.67M (in $), with an average increase of 5.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -50.54M → -21.40M (in $), with an average increase of 136.1% per quarter

Glaukos Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$181.3M	↑ 13.83%
Net Income	$-13.0M	↑ 13977.17%
Net Profit Margin	-7.14%	↓ 7.08%

	FY19	Y/Y Change
Revenue	$237.0M	↑ 30.73%
Net Income	$15.4M	↓ 219.1%
Net Profit Margin	6.51%	↑ 13.65%

	FY20	Y/Y Change
Revenue	$225.0M	↓ 5.07%
Net Income	$-120.3M	↓ 880.26%
Net Profit Margin	-53.5%	↓ 60.01%

	FY21	Y/Y Change
Revenue	$294.0M	↑ 30.7%
Net Income	$-49.6M	↓ 58.79%
Net Profit Margin	-16.87%	↑ 36.63%

	FY22	Y/Y Change
Revenue	$282.9M	↓ 3.79%
Net Income	$-99.2M	↑ 100.02%
Net Profit Margin	-35.07%	↓ 18.2%

	FY23	Y/Y Change
Revenue	$314.7M	↑ 11.26%
Net Income	$-134.7M	↑ 35.75%
Net Profit Margin	-42.79%	↓ 7.72%

	Q2 FY23	Q/Q Change
Revenue	$80.4M	↑ 8.8%
Net Income	$-32.8M	↓ 5.24%
Net Profit Margin	-40.81%	↑ 6.05%

	Q3 FY23	Q/Q Change
Revenue	$78.0M	↓ 2.92%
Net Income	$-30.4M	↓ 7.22%
Net Profit Margin	-39.01%	↑ 1.8%

	Q4 FY23	Q/Q Change
Revenue	$82.4M	↑ 5.53%
Net Income	$-36.8M	↑ 20.81%
Net Profit Margin	-44.65%	↓ 5.64%

	Q1 FY24	Q/Q Change
Revenue	$85.6M	↑ 3.95%
Net Income	$-40.8M	↑ 11.04%
Net Profit Margin	-47.7%	↓ 3.05%

	Q2 FY24	Q/Q Change
Revenue	$95.7M	↑ 11.76%
Net Income	$-50.5M	↑ 23.77%
Net Profit Margin	-52.82%	↓ 5.12%

	Q3 FY24	Q/Q Change
Revenue	$96.7M	↑ 1.02%
Net Income	$-21.4M	↓ 57.64%
Net Profit Margin	-22.15%	↑ 30.67%

	FY18	Y/Y Change
Profit	$156.2M	↑ 13.02%

	FY19	Y/Y Change
Profit	$198.4M	↑ 27.01%

	FY20	Y/Y Change
Profit	$133.2M	↓ 32.84%

	FY21	Y/Y Change
Profit	$227.4M	↑ 70.66%

	FY22	Y/Y Change
Profit	$213.9M	↓ 5.94%

	FY23	Y/Y Change
Profit	$239.1M	↑ 11.81%

	Q2 FY23	Q/Q Change
Profit	$60.3M	↑ 8.0%

	Q3 FY23	Q/Q Change
Profit	$59.5M	↓ 1.26%

	Q4 FY23	Q/Q Change
Profit	$63.5M	↑ 6.61%

	Q1 FY24	Q/Q Change
Profit	$65.4M	↑ 2.98%

	Q2 FY24	Q/Q Change
Profit	$73.1M	↑ 11.9%

	Q3 FY24	Q/Q Change
Profit	$74.1M	↑ 1.29%

	FY18	Y/Y Change
Operating Cash Flow	$18.9M	↓ 26.05%
Investing Cash Flow	$-26.4M	↑ 125.12%
Financing Cash Flow	$21.6M	↑ 362.31%

	FY19	Y/Y Change
Operating Cash Flow	$-369.0K	↓ 101.96%
Investing Cash Flow	$43.4M	↓ 264.49%
Financing Cash Flow	$-9.6M	↓ 144.7%

	FY20	Y/Y Change
Operating Cash Flow	$-23.0M	↑ 6129.81%
Investing Cash Flow	$-205.1M	↓ 572.21%
Financing Cash Flow	$262.5M	↓ 2822.05%

	FY21	Y/Y Change
Operating Cash Flow	$24.7M	↓ 207.48%
Investing Cash Flow	$-58.2M	↓ 71.6%
Financing Cash Flow	$39.3M	↓ 85.05%

	FY22	Y/Y Change
Operating Cash Flow	$-33.1M	↓ 233.9%
Investing Cash Flow	$44.8M	↓ 176.9%
Financing Cash Flow	$6.3M	↓ 84.08%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-8.2M	↓ 73.47%
Investing Cash Flow	$26.0M	↓ 287.62%
Financing Cash Flow	$-880.0K	↓ 176.39%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-8.2M	↑ 0.09%
Investing Cash Flow	$14.9M	↓ 42.6%
Financing Cash Flow	$7.5M	↓ 948.52%

Glaukos Technicals Summary

Sell

Neutral

Buy

Glaukos is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Glaukos Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Glaukos Corp	7.14%	34.74%	83.24%	230.51%	165.59%
Boston Scientific Corp.	-2.79%	15.96%	59.12%	110.98%	96.7%
Stryker Corporation	-6.55%	7.53%	22.55%	38.08%	71.54%
Edwards Lifesciences Corp.	6.29%	-17.03%	-1.35%	-41.48%	-5.43%
Abbott Laboratories	-2.58%	8.48%	4.77%	-17.81%	30.77%
Medtronic Plc	-4.38%	-0.01%	-1.09%	-20.04%	-28.85%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Glaukos Corp	NA	NA	1.64	-1.83	-0.26	-0.08	NA	12.13
Boston Scientific Corp.	73.27	73.27	1.61	2.46	0.09	0.05	NA	14.05
Stryker Corporation	38.32	38.32	2.51	12.06	0.19	0.07	0.01	52.86
Edwards Lifesciences Corp.	28.88	28.88	6.79	2.55	0.19	0.11	NA	16.18
Abbott Laboratories	34.17	34.17	2.17	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	24.46	24.46	1.46	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Glaukos Corp	Buy	$7.9B	165.59%	NA	-41.51%
Boston Scientific Corp.	Buy	$130.7B	96.7%	73.27	11.26%
Stryker Corporation	Buy	$136.1B	71.54%	38.32	16.34%
Edwards Lifesciences Corp.	Buy	$44.1B	-5.43%	28.88	65.86%
Abbott Laboratories	Buy	$195.0B	30.77%	34.17	13.99%
Medtronic Plc	Buy	$102.6B	-28.85%	24.46	12.06%

Glaukos Dividend announcements

Glaukos Earnings
Glaukos’s price-to-earnings ratio stands at None
Read More

About Glaukos

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde

Organization	Glaukos
Employees	907
CEO	Mr. Thomas William Burns
Industry	Health Technology

Management People of Glaukos

Name	Title
Mr. Thomas William Burns	Chairman & CEO
Mr. Joseph E. Gilliam	President & COO
Mr. Alex R. Thurman	Senior VP & CFO
Dr. Tomas Navratil Ph.D.	Chief Development Officer
Dr. Mory Gharib Ph.D.	Co-Founder
Mr. Christopher William Lewis	Vice President of Investor Relations & Corporate Affairs
Mr. Robert L. Davis J.D.	Senior VP, General Counsel & Business Development
Ms. Diana A. Scherer	VP of Compliance & Deputy General Counsel
Ms. Michele M. Allegretto	Senior Vice President of Human Resources
Mr. Chris M. Calcaterra	Executive Vice President of Global Commercial Operations

Important FAQs about investing in Glaukos from India :

What is Glaukos share price today?

Glaukos share price today stands at $150.88, Open: $141.53 ; Previous Close: $143.74 ; High: $150.99 ; Low: $142.84 ; 52 Week High: $151.12 ; 52 Week Low: $74.75. The stock opens at $141.53, after a previous close of $143.74. The stock reached a daily high of $150.99 and a low of $142.84, with a 52-week high of $151.12 and a 52-week low of $74.75.

Can Indians buy Glaukos shares?

Yes, Indians can invest in the Glaukos (GKOS) from India.

With INDmoney, you can buy Glaukos at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Glaukos at zero transaction cost.

How can I buy Glaukos shares from India?

It is very easy to buy Glaukos from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Glaukos be purchased?

Yes, you can buy fractional shares of Glaukos with INDmoney app.

What are the documents required to start investing in Glaukos stocks?

To start investing in Glaukos, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.